This list price is more than double the ICER valuation on the CAR. I don’t think the European health authorities are going to green light this CAR at this price. I don’t see Europe paying over $200,000/dose since they don’t care about @NIH fees and/or royalties. $BLUE $BMY
https://twitter.com/transplant_doc/status/1377094599487803396
This also highlights a much bigger problem with CARs, esp. for solid tumors. It’s a problem we have always prepared for at SES but could hurt our competitors that plan to charge over $400,000/dose. In solid tumors, if the CARs aren’t curative, they have to be really cheap!
The CARs won’t be curative in solid tumors initially — esp. for the first CARs approved for solid tumors — so companies that think they can charge $400,000+/dose are going to be in for a rude awakening. It’s hard to justify that price tag for next gen CARs. #CARTcells
We’ve been aiming for the goal of $100,000/dose or less at SES. If for some reason we can’t hit that price goal, we will be transparent about why that is, but we continue to plan for disruptively cheap #CARTcells. We are the only US CAR company worried about affordability.
When you are facing a cancer diagnosis, worrying about how to pay for treatment should be the furthest thing from your mind. If you wonder why our competitors hate us, it’s because we care about YOU.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
